Search research articles
Contact Us
Filters
Showing results (91-100 of 165) with videos related to
Page
of 17
Sort By:
Geburtshilfe Und Frauenheilkunde
|
November 11, 2020
Update Breast Cancer 2020 Part 3 - Early Breast Cancer
Jens Huober, Andreas Schneeweiss, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde
|
August 24, 2023
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare
Volkmar Müller, Peter A Fasching, Naiba Nabieva, et al.
Geburtshilfe Und Frauenheilkunde
|
August 4, 2017
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)
Michael Untch, Jens Huober, Christian Jackisch, et al.
Geburtshilfe Und Frauenheilkunde
|
April 19, 2021
Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients
Michael P Lux, Andreas Schneeweiss, Andreas D Hartkopf, et al.
Journal of Cancer Research and Clinical Oncology
|
June 19, 2025
The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer - the SERAPHINA study
Andreas Schneeweiss, Peter A Fasching, Marc Thill, et al.
JAMA Oncology
|
May 19, 2022
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Jens-Uwe Blohmer, Theresa Link, Mattea Reinisch, et al.
JAMA Oncology
|
January 13, 2018
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial
Luca Gianni, Mauro Mansutti, Antonio Anton, et al.
Frontiers in Oncology
|
February 28, 2022
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Alberto Ocaña, Jose Ignacio Chacón, Lourdes Calvo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2023
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial
Theresa Link, Jens-Uwe Blohmer, Wolfgang D Schmitt, et al.
Geburtshilfe Und Frauenheilkunde
|
June 13, 2025
Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer
Diana Lüftner, Maggie Banys-Paluchowski, Andreas D Hartkopf, et al.
Page
of 17
Search research articles
Search
Showing results (91-100 of 165) with videos related to
Sort By:
Page
of 17
Geburtshilfe Und Frauenheilkunde
|
November 11, 2020
Update Breast Cancer 2020 Part 3 - Early Breast Cancer
Jens Huober, Andreas Schneeweiss, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde
|
August 24, 2023
Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare
Volkmar Müller, Peter A Fasching, Naiba Nabieva, et al.
Geburtshilfe Und Frauenheilkunde
|
August 4, 2017
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)
Michael Untch, Jens Huober, Christian Jackisch, et al.
Geburtshilfe Und Frauenheilkunde
|
April 19, 2021
Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients
Michael P Lux, Andreas Schneeweiss, Andreas D Hartkopf, et al.
Journal of Cancer Research and Clinical Oncology
|
June 19, 2025
The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer - the SERAPHINA study
Andreas Schneeweiss, Peter A Fasching, Marc Thill, et al.
JAMA Oncology
|
May 19, 2022
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Jens-Uwe Blohmer, Theresa Link, Mattea Reinisch, et al.
JAMA Oncology
|
January 13, 2018
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial
Luca Gianni, Mauro Mansutti, Antonio Anton, et al.
Frontiers in Oncology
|
February 28, 2022
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Alberto Ocaña, Jose Ignacio Chacón, Lourdes Calvo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2023
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial
Theresa Link, Jens-Uwe Blohmer, Wolfgang D Schmitt, et al.
Geburtshilfe Und Frauenheilkunde
|
June 13, 2025
Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer
Diana Lüftner, Maggie Banys-Paluchowski, Andreas D Hartkopf, et al.
Page
of 17